Screener
LivaNova LIVN Neuromodulation — Selling, general, and administrative
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by LivaNova in its filing.
Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.
The source filing: LivaNova’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 2:23 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001639691-26-000090
| Line item | Cardiopulmonary / Three Months Ended June 30, 2026 | Cardiopulmonary / Three Months Ended June 30, 2025 | Neuromodulation / Three Months Ended June 30, 2026 | Neuromodulation / Three Months Ended June 30, 2025 |
|---|---|---|---|---|
| Net revenue | $221,576 | $199,272 | $166,945 | $151,670 |
| Less: | ||||
| Cost of sales | 97,265 | 95,465 | 14,455 | 14,769 |
| Selling, general, and administrative | 66,465 | 56,012 | 56,568 | 51,097 |
| Research and development | 18,376 | 16,465 | 34,987 | 29,784 |
| 3T litigation provision | 11,318 | (77) | — | — |
| $28,152 | $31,407 | $60,935 | $56,020 | |
| Cardiopulmonary | Neuromodulation |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is LivaNova's neuromodulation — selling, general, and administrative?
- LivaNova (LIVN) reported neuromodulation — selling, general, and administrative of $56.57M in Q2 2026.
- How has LivaNova's neuromodulation — selling, general, and administrative changed year-over-year?
- LivaNova's neuromodulation — selling, general, and administrative increased by 10.7% year-over-year, from $51.1M to $56.57M.
- What is the long-term trend for LivaNova's neuromodulation — selling, general, and administrative?
- Over 3 years (2022 to 2025), LivaNova's neuromodulation — selling, general, and administrative has grown at a 8.4% compound annual growth rate (CAGR), from $158.98M to $202.6M.
- What does neuromodulation — selling, general, and administrative mean?
- Captures the indirect costs associated with operating the Neuromodulation segment, including sales force compensation, marketing, and general corporate overhead. It reflects the level of investment required to support and grow the segment's market presence.
Ask your AI about LivaNova's neuromodulation — selling, general, and administrative.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude